Wang Yao-Tung, Liu Hsu-Chung, Chen Hui-Chen, Lee Yen-Ching, Tsai Tung-Chou, Chen Hsiao-Ling, Fan Hueng-Chuen, Chen Chuan-Mu
1Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
2School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Allergy Asthma Clin Immunol. 2018 Oct 16;14:43. doi: 10.1186/s13223-018-0269-2. eCollection 2018.
Allergen-specific immunotherapy (ASIT) has the potential to modify allergic diseases, and it is also considered a potential therapy for allergic asthma. House dust mite (HDM) allergens, a common source of airborne allergen in human diseases, have been developed as an immunotherapy for patients with allergic asthma via the subcutaneous and sublingual routes. Oral immunotherapy with repeated allergen ingestion is emerging as another potential modality of ASIT. The aim of this study was to evaluate the therapeutic efficacy of the oral ingestion of HDM extracts in a murine model of allergic asthma.
BABL/c mice were sensitized twice by intraperitoneal injection of HDM extracts and Al(OH) on day 1 and day 8. Then, the mice received challenge to induce airway inflammation by intratracheal instillation of HDM extracts on days 29-31. The treatment group received immunotherapy with oral HDM extracts ingestion before the challenge. All the mice were sacrificed on day 32 for bronchoalveolar inflammatory cytokines, mediastinal lymph node T cells, lung histology, and serum HDM-specific immunoglobulins analyses.
Upon HDM sensitization and following challenge, a robust Th2 cell response and eosinophilic airway inflammation were observed in mice of the positive control group. The mice treated with HDM extracts ingestion had decreased eosinophilic airway inflammation, suppressed HDM-specific Th2 cell responses in the mediastinal lymph nodes, and attenuated serum HDM-specific IgE levels.
Oral immunotherapy with HDM extracts ingestion was demonstrated to have a partial therapeutic effect in the murine model of allergic asthma. This study may serve as the basis for the further development of oral immunotherapy with HDM extracts in allergic asthma.
变应原特异性免疫疗法（ASIT）有可能改变过敏性疾病，也被认为是过敏性哮喘的一种潜在治疗方法。屋尘螨（HDM）变应原是人类疾病中空气传播变应原的常见来源，已通过皮下和舌下途径开发用于过敏性哮喘患者的免疫疗法。通过反复摄入变应原进行口服免疫疗法正在成为ASIT的另一种潜在方式。本研究的目的是评估在过敏性哮喘小鼠模型中口服HDM提取物的治疗效果。
BABL/c小鼠在第1天和第8天通过腹腔注射HDM提取物和氢氧化铝进行两次致敏。然后，在第29 - 31天通过气管内滴注HDM提取物对小鼠进行激发以诱导气道炎症。治疗组在激发前接受口服HDM提取物的免疫疗法。所有小鼠在第32天处死，用于支气管肺泡炎性细胞因子、纵隔淋巴结T细胞、肺组织学和血清HDM特异性免疫球蛋白分析。
在HDM致敏和激发后，在阳性对照组小鼠中观察到强烈的Th2细胞反应和嗜酸性气道炎症。口服HDM提取物治疗的小鼠嗜酸性气道炎症减轻，纵隔淋巴结中HDM特异性Th2细胞反应受到抑制，血清HDM特异性IgE水平降低。
在过敏性哮喘小鼠模型中，口服HDM提取物免疫疗法被证明具有部分治疗效果。本研究可为进一步开发HDM提取物口服免疫疗法治疗过敏性哮喘提供依据。
